Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG
- 1 September 1987
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 93 (1) , 31-35
- https://doi.org/10.1007/bf02439583
Abstract
Ten patients with Alzheimer's disease were treated with intravenous infusion of physostigmine for 2 h. The acute effects on cognitive function, regional cerebral blood flow, and EEG were compared to placebo (isotonic glucose) using a double-blind cross-over design. Physostigmine causes a limited improvement of psychomotor performance and EEG and an increase of blood flow in the most severely affected cortical areas, predominantly in an early phase of Alzheimer's disease.This publication has 30 references indexed in Scilit:
- Acute Administration of Individual Optimal Dose of Physostigmine Fails to Improve Mnesic Performances in Alzheimers Presenile DementiaInternational Journal of Neuroscience, 1983
- Oral Administration of Chronic Physostigmine does not Improve Cognitive or Mnesic Performances in Alzheimer's Presenile DementiaInternational Journal of Neuroscience, 1982
- Physostigmine and Arecoline: Effects of Intravenous Infusions in Alzheimer Presenile DementiaThe British Journal of Psychiatry, 1981
- EEG effects of physostigmine and choline chloride in humansPsychopharmacology, 1979
- ACCELERATED AGEING OR SELECTIVE NEURONAL LOSS AS AN IMPORTANT CAUSE OF DEMENTIA?The Lancet, 1979
- Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brainsBrain Research, 1977
- SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASEPublished by Elsevier ,1976
- NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIESBrain, 1976
- REM Sleep Induction by Physostigmine Infusion During SleepScience, 1976
- Regional Cerebral Blood Flow Estimated by 133 Xenon InhalationStroke, 1975